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switchers who increased imatinib dose to 400 mg/day (dose escalators) were then
followed until treatment discontinuation or end of eligibility. Negative binomial 
regression models were used to compare resource utilization associated with dose 
escalators vs. switchers, controlling for demographics, baseline imatinib treatment 
patterns, therapies, adverse events, and resource utilization. Cox regression models 
were used to study hospice services and stem cell transplants during the follow-up
period among patients without such prior event. RESULTS: Among CML patients 
who initiated on imatinib, 474 dose escalators and 175 dasatinib switchers were 
identiﬁ ed. Compared to dose escalators, switchers had signiﬁ cantly more frequent
inpatient visits (incidence rate ratio [IRR]  3.37, p  .005), emergency room visits
(IRR  1.80, p  .018), and outpatient visits (IRR 1.38 p  .001). Although low in
absolute rates, switchers had substantially higher risks of hospice use (hazard ratio 
[HR]  14.55, p  .066) and stem cell transplant (HR  8.71, p  0.006), indicating 
deteriorated clinical outcomes. CONCLUSIONS: Imatinib-treated CML patients who 
switched to dasatinib are associated with signiﬁ cantly more intensive resource utiliza-
tion and adverse clinical outcomes than those who escalated to higher doses. Further
studies are warranted to examine the causality of the differences in resource utilization
and clinical outcomes.
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OBJECTIVES: In the present study, physicians’ beliefs about patients’ preferences 
regarding the treatment of MM were explored in a direct assessment and a Discrete
Choice Experiment (DCE) and were compared to the previously explored patients’
preferences. METHODS: In a preceding DCE with MM-patients, relevant attributes 
of an ideal MM-treatment were collected by reviewing the literature and by conducti-
ng a qualitative study with four focus groups. The attributes were analyzed in a
subsequent quantitative study using both a direct measurement (16 items on a
5-point Likert-scale) and a DCE (8 pairs with 8 characteristics). In the present 
study, 243 physicians answered (76% male, 62% haematology specialists, 70%
with 10 MM-patients in the last 12 months) the identical questionnaire. RESULTS:
Physicians rated physical quality of life (speciﬁ ed as “reduced mobility or good
mobility”), rare side effects and effectiveness aspects (duration of effect, maximal 
prolonged life expectancy and effectiveness) as most important attributes from the
patients’ perspective. While the direct assessment gathers a range of important aspects,
weighing particular relevant treatment attributes in a DCE is important. Physicians
ranked prolonged life expectancy as most relative important and signiﬁ cantly more
important than all other treatment attributes. Further treatment options were second 
most important and signiﬁ cant compared to breaks in therapy and physical quality of 
life, whereas the patients ordered these two top priorities reversely. CONCLUSIONS:
Over a broad range of treatment attributes the physicians’ perceptions of preferences 
were very close to those of MM patients. However in the DCE, after weighing the
attributes patients assigned a higher relative importance to further treatment options 
and “Not always think of the disease”, but less to prolonged life expectancy and 
self-application.
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OBJECTIVES: The aim of this study was to describe health related quality of life in 
different stages of non-hodgkin lymphoma in patients attended in a tertiary referral
center at the Social Security Mexican Institute. METHODS: Were included outpatients 
with non-hodgkin lymphoma, attended in a tertiary referral center since July to 
August 2008, with the following inclusion criteria: older than 16 years, non-hodgkin 
lymphoma histological diagnosis, were included through informed consent; were
excluded patients with second malignant neoplasm or incomplete information. To 
calculate health related quality of life EORTC QLQ-C30 score validated Spanish
version to México was used; were evaluated global health status, functional scales
(physical, role, emotional, cognitive, social) and symptom scales (fatigue, nausea and 
vomiting, pain, dyspnea, insomnia, appetite loss, constipation, diarrhea, ﬁ nancial dif-
ﬁ culties) in scale since 0 to 100 (0  death, 100  perfect health). Were calculated 
means and range for EORTC QLQ-C30 score items; statistical differences were cal-
culated through ANOVA test, p value 0.05 was considered signiﬁ cant. RESULTS:
We studied 14 non-hodgkin lymphoma patients, mean age group was 60 o 12.3 years
old, 57% were women, 78% were married, and 23% had an educational level
of incomplete elementary school. The stating of this group was distributed as follow:
I-7%, II-14%, III-7% and NC (non classiﬁ ed)-72% (without complete histopathology
report at interview moment). Health related quality of life mean for all items was: 
I:88.2, II:87.6, III:48.11, according clinical stage in NC group was 75.1; p  0.23. 
The assumptions associated with a decreased health related quality of life associated 
with disease progression were emotional function (I-83, II-63, III-66; p  0.05), cogni-
tive function (I-10, II-83, III-50, IV-56; p  0.06). CONCLUSIONS: We observed a
decreased health related quality of life associated with a late clinical stage in emotional
and cognitive function.
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OBJECTIVES: The aim of this study was to describe health related quality of life
in different stages of breast cancer in patients attended in a tertiary referral center 
at the Social Security Mexican Institute. METHODS: Were included outpatients 
with breast cancer, attended in a tertiary referral center since July to August 2008,
with the following inclusion criteria: older than 16 years, breast cancer histological 
diagnosis, accepted were included through informed consent, were excluded patients 
with second malignant neoplasm or incomplete information. To calculate health 
related quality of life EORTC QLQ-C30 score validated Spanish version to México 
was used; were evaluated global health status, functional scales (physical, role, emo-
tional, cognitive, social) and symptom scales (fatigue, nausea and vomiting, pain, 
dyspnea, insomnia, appetite loss, constipation, diarrhea, ﬁ nancial difﬁ culties) in scale 
since 0 to 100 (0  death, 100  perfect health). Were calculated means and range for 
EORTC QLQ-C30 score items; statistical differences were calculated through ANOVA
test, p value 0.05 was considered signiﬁ cant. RESULTS: We studied 148 breast cancer
patients, mean age 51.68 o 10.32 years old, 69% were married, and 20% had an
educational level of preparatory school. The stating of this group was distributed 
according clinical stage as follow: I-6%, II-23%, III-16%, IV-7% without stage at 
interview moment (NC) 47% (ﬁ rst visit for diagnosis). Health related quality of life 
mean for all items was: I:85.7 o 7, II:75.36 o 15, III:74.47 o 17 and IV:61.05 o 22, 
NC:76 o 18 (p  0.07). The assumptions associated with a decreased health related 
quality of life in relation to late clinical stage were physical function (I-88, II-79, III-75, 
IV-56; p  0.003), role function (I-90, II-80, III-71, IV-43; p  0.001), weakness 
(I-83, II-66, III-62, IV-44; p  0.004) and pain (I-85, II-70, III-65, IV-50; p  0.05). 
CONCLUSIONS: We observed decreased health related quality of life in late clinical
stage. An important factor with impact in quality life could be adverse events related 
with adjuvant treatments.
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OBJECTIVES: The aim of this study was to describe health related quality of life in 
different stages of colorectal cancer in patients attended in a tertiary referral center at 
the Social Security Mexican Institute. METHODS: Were included outpatients with 
colorectal cancer, attended in a tertiary referral center since July to August 2008, with
the following inclusion criteria: older than 16 years, colorectal cancer histological 
diagnosis, accepted were included through informed consent; were excluded patients 
with second malignant neoplasm or incomplete information. To calculate health related 
quality of life EORTC QLQ-C30 score validated Spanish version to México was used; 
were evaluated global health status, functional scales (physical, role, emotional, cogni-
tive, social) and symptom scales (fatigue, nausea and vomiting, pain, dyspnea, insom-
nia, appetite loss, constipation, diarrhea, ﬁ nancial difﬁ culties) in scale since 0 to 100
(0  death, 100  perfect health). Were calculated means and range for EORTC QLQ-
C30 score items; statistical differences were calculated through ANOVA test, p value 
0.05 was considered signiﬁ cant. RESULTS: We studied 31 colorectal cancer patients,
mean age patients was 55 o 11.5 years old, 54% were women, 71% were married, 
and 38% had secondary school. The stating of this group was distributed as follow: 
II-4 (13%), III-2 (6%) IV-7 (23%) and NC (non-classiﬁ ed)-18 (58%) (without complete
histopathology report). Health related quality of life mean according stage for all items 
was: II:57 o 22, III:86 o 12 and IV:66 o 14 NC 76 o 19 (p  0.17) The assumptions 
associated with a decreased health related quality of life associated with disease pro-
gression were pain (II-20, III-75, IV-52;p  0.02) and ﬁ nancial problems (II-25, III-100,
IV-76;p  0.09. CONCLUSIONS: We observed a decreased health related quality of 
life associated with late clinical stage by pain and ﬁ nancial problems.
